Related Experiment Video
Updated: Sep 11, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Network pharmacology and molecular docking-based strategy to determine the potential mechanism for
Chuanjun Zhuo1, Ying Zhang1, Chao Li1
1Laboratory of Computational Biology and Computational Psychiatry (CBCP-Lab), Tianjin Anding Hospital, Nankai University Affiliated Tianjin Anding Hospital, Tianjin Medical University Affiliated Tianjin Mental Health Center, Tianjin 300222, China; Laboratory of Psychiatric-Neuroimaging-Genetic and Co-morbidity (PNGC-Lab), Tianjin Anding Hospital, Nankai University Affiliated Tianjin Anding Hospital, Tianjin Mental Health Center of Tianjin Medical University, Tianjin 300222, China.
Background:
The objective of this study was to identify the potential molecular mechanisms for escitalopram-mediated development of long QT syndrome (LQTS) using network pharmacology and molecular docking.
Method:
Targets related to LQTS were obtained from the GeneCards, DisGeNET, and OMIM databases, while targets related to escitalopram were retrieved from the PharmMapper, SwissTargetPrediction, SuperPred, GeneCards, DrugBank, and SEA databases. A Venn diagram containing drug-disease intersection targets was generated using the Bioinformatics online tool. A protein-protein interaction network was developed using the STRING database. Core targets were screened using Cytoscape, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of escitalopram-LQTS intersection targets were performed using DAVID. A drug-disease-target pathway network was developed with Cytoscape. AutoDock Vina and PyMOL software were used for molecular docking analyses.
Results:
Six potential targets of escitalopram-mediated LQTS, including TNF, IL-1β, INS, SRC, STAT3, and GSK-3β, were shown to bind well to escitalopram in molecular docking analyses. The KEGG enrichment analysis suggested that escitalopram caused adverse LQTS reactions by modulating prolactin and lipid levels, atherosclerosis, and the calcium signaling pathway.
Limitations:
Further in vitro or molecular biology experiments are needed to validate the mechanism identified in this study by which escitalopram induced LQTS.
Conclusions:
Based on bioinformatic analysis, escitalopram may affect the electrolyte balance, atherosclerosis, and ion channels implicated in LQTS, providing theoretical clues for follow-up studies.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
05:47In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Drugs Affecting Neurotransmitter Release or Uptake